[{"id":"1a4083a5-4479-438a-a119-f10ee1b03fe4","acronym":"PICAROS","url":"https://clinicaltrials.gov/study/NCT05999877","created_at":"2023-08-21T15:08:51.118Z","updated_at":"2024-07-02T16:34:26.928Z","phase":"","brief_title":"PICAROS - Acalabrutinib RWE on 1L CLL in Spain","source_id_and_acronym":"NCT05999877 - PICAROS","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation + Chr del(17p)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation + Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-12"},{"id":"26912b3a-874b-41d0-8280-5bf68e728ed7","acronym":"IOV-CLL-01","url":"https://clinicaltrials.gov/study/NCT04155710","created_at":"2021-01-18T20:16:34.491Z","updated_at":"2024-07-02T16:35:04.463Z","phase":"Phase 1/2","brief_title":"Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL","source_id_and_acronym":"NCT04155710 - IOV-CLL-01","lead_sponsor":"Iovance Biotherapeutics, Inc.","biomarkers":" TP53 • IL2","pipe":" | ","alterations":" TP53 mutation • TP53 mutation + Chr del(17p)","tags":["TP53 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 mutation + Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IOV-2001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/19/2020","start_date":" 02/19/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-10"},{"id":"55f48584-0a3e-41d6-a7ea-babf85b2ff5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03342144","created_at":"2021-01-18T16:30:28.943Z","updated_at":"2024-07-02T16:35:36.565Z","phase":"","brief_title":"Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting","source_id_and_acronym":"NCT03342144","lead_sponsor":"AbbVie","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 mutation + Chr del(17p)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 mutation + Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 12/04/2017","start_date":" 12/04/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-21"},{"id":"a128a1ac-0eb5-4f86-bf66-e42941b658e4","acronym":"BET2017","url":"https://clinicaltrials.gov/study/NCT03823365","created_at":"2021-01-18T18:53:08.869Z","updated_at":"2024-07-02T16:36:19.196Z","phase":"Phase 1","brief_title":"Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT03823365 - BET2017","lead_sponsor":"A.O. Ospedale Papa Giovanni XXIII","biomarkers":" TP53 • CD20 • CD8","pipe":" | ","alterations":" TP53 mutation • TP53 mutation + Chr del(17p)","tags":["TP53 • CD20 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 mutation + Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Blincyto (blinatumomab) • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 12/17/2018","start_date":" 12/17/2018","primary_txt":" Primary completion: 11/11/2021","primary_completion_date":" 11/11/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2021-12-23"},{"id":"43cc2176-b27f-4bca-b397-b12e19417b2d","acronym":"iLLUMINATE ","url":"https://clinicaltrials.gov/study/NCT02264574","created_at":"2021-01-17T17:35:09.358Z","updated_at":"2024-07-02T16:36:40.852Z","phase":"Phase 3","brief_title":"A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT02264574 - iLLUMINATE ","lead_sponsor":"Pharmacyclics LLC.","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Leukeran (chlorambucil)"],"overall_status":"Completed","enrollment":" Enrollment 229","initiation":"Initiation: 10/06/2014","start_date":" 10/06/2014","primary_txt":" Primary completion: 03/26/2018","primary_completion_date":" 03/26/2018","study_txt":" Completion: 09/03/2019","study_completion_date":" 09/03/2019","last_update_posted":"2020-09-21"}]